A cardiovascular risk calculator for renal transplant recipients

Transplantation

Volumn 94, Issue 1, 2012, Pages 57-62

  Soveri, Inga ^a   Holme, Ingar ^b   Holdaas, Hallvard ^c   Budde, Klemens ^d   Jardine, Alan G ^e   Fellström, Bengt ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular events; Mortality; Renal transplant recipients; Risk assessment; Validation

Indexed keywords

CREATININE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN;

ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; ARTICLE; CALIBRATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SMOKING; VALIDATION PROCESS;

ADULT; CALIBRATION; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RISK; ROC CURVE;

EID: 84863717171     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182516cdc     Document Type: Article

References (27)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154.
2. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
3. Artz MA, Boots JM, Ligtenberg G, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14: 1880.
4. Rike AH, Mogilishetty G, Alloway RR, et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant 2008; 22: 229.
5. Rogers CC, Alloway RR, Boardman R, et al. Global cardiovascular risk under early corticosteroid cessation decreases progressively in the first year following renal transplantation. Transplant Proc 2005; 37: 812.
6. Woodle ES. A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report. Transplant Proc 2005; 37: 804.
7. KramerBK, ZulkeC,KammerlMC, et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3: 982.
8. Marcen R, Chahin J, Alarcon A, et al. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. Transplant Proc 2006; 38: 2427.
9. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framinghamriskmodel. Am J Transplant 2002; 2: 551.
10. Hernandez D, Sanchez-Fructuoso A, Gonzalez-Posada JM, et al. A novel risk score for mortality in renal transplant recipients beyond the first posttransplant year. Transplantation 2009; 88: 803.
11. Israni AK, Snyder JJ, SkeansMA, et al. Predicting coronary heart disease after kidney transplantation: PatientOutcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010; 10: 338.
12. Hernandez D, Rufino M, Bartolomei S, et al. A novel prognostic index for mortality in renal transplant recipients after hospitalization. Transplantation 2005; 79: 337.
13. Jardine AG, Fellström B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study. Am J Kidney Dis 2005; 46: 529.
14. ConroyRM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987.
15. Silver SA, Huang M, Nash MM, et al. Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients. Transplantation 2011; 92: 183.
16. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66: 441.
17. Kiberd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol 2008; 3: 822.
18. Kiberd B, Keough-Ryan T, Panek R. Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am J Transplant 2003; 3: 1393.
19. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: fromarea under theROC curve to reclassification and beyond. Stat Med 2008; 27: 157.
20. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107.
21. SoveriI,ArnlovJ,BerglundL,et al. Kidney function and discrimination of cardiovascular risk in middle-aged men. J Intern Med 2009; 266: 406.
22. Altman DG, Vergouwe Y, Royston P, et al. Prognosis and prognostic research: validating a prognostic model. BMJ 2009; 338: b605.
23. Pita-Fernandez S, Pertega-Diaz S, Valdes-Canedo F, et al. Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol. BMC Cardiovasc Disord 2011; 11: 2.
24. Holdaas H, Fellstrom B, Holme I, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J CardiovascRisk 2001; 8: 63.
25. HoldaasH, FellstromB, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024.
26. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5: 2929.
27. Soveri I, Holdaas H, Jardine A, et al. Renal transplant dysfunctionV importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006; 21: 2282.